Figure 5.

CRMP2 synergized with CRMP4 in axon growth but not axon guidance. A half dose of either CRMP2 or CRMP4 MOs was injected singly or in combination. (a, b) Representative examples of knocking down effects of CRMP2 and CRMP4 MOs in combination. (c) The combination of the two MOs causes a significantly higher percentage of axon growth defects than the sum of the defects caused by adding up the single half doses (Fisher's exact test, P < 0.001). (d) No obvious synergy between the two CRMPs in retinal axon guidance. The doses of MOs are labeled under each column. The numbers in parentheses above each column indicate the amount of eyes.